Chloe Botaine sat down with Ivan Kairatov, a Biopharma expert with deep R&D and tech experience, to discuss the European Commission’s approval of a long-acting monoclonal antibody for RSV prevention in newborns and infants. With a single intramuscular dose designed to protect for up to five months,
For patients living with a chronic Achilles rupture that has resisted months of therapy and bracing, every step can feel like a wager against pain, weakness, instability, and the fear that a compromised tendon will fail again during even the simplest tasks. Traditional reconstruction can fix the
A disease that steals movement while leaving thought intact demanded more than incremental symptom care, and that urgency set the stage for a candidate built to confront the fault line where motor neurons first begin to fail. AP-2, now entering first-in-human testing at La Princesa University
Ivan Kairatov brings a biopharma lens to one of the most sensitive decisions in pediatrics: when to give the first hepatitis B vaccine. With a research-and-development background rooted in tech and innovation, he translates probabilistic modeling, clinical epidemiology, and practical workflows into
Swift regulatory action upended a fragile corner of San Antonio’s behavioral health system when federal officials moved to terminate Medicare and Medicaid participation for a major psychiatric hospital that treats children, adolescents, adults, veterans, and people with substance use disorders,
Admission to GLP-1 therapy once crawled through a maze of clinic calendars, phone tag, and insurer scripts, but a wave of purpose-built telehealth apps has turned that maze into a guided lane on a phone that now functions as both navigator and engine. The change was not merely cosmetic. Adaptive
